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Abstract
Antiretroviral therapy (ART) has reduced morbidity and mortality in HIV-1 infection; however HIV-1-associated
neurocognitive disorders (HAND) persist despite treatment. The reasons for the limited efficacy of ART in the brain are
unknown. Here we used functional genomics to determine ART effectiveness in the brain and to identify molecular
signatures of HAND under ART. We performed genome-wide microarray analysis using Affymetrix U133 Plus 2.0 Arrays, real-
time PCR, and immunohistochemistry in brain tissues from seven treated and eight untreated HAND patients and six
uninfected controls. We also determined brain virus burdens by real-time PCR. Treated and untreated HAND brains had
distinct gene expression profiles with ART transcriptomes clustering with HIV-1-negative controls. The molecular disease
profile of untreated HAND showed dysregulated expression of 1470 genes at p,0.05, with activation of antiviral and
immune responses and suppression of synaptic transmission and neurogenesis. The overall brain transcriptome changes in
these patients were independent of histological manifestation of HIV-1 encephalitis and brain virus burdens. Depending on
treatment compliance, brain transcriptomes from patients on ART had 83% to 93% fewer dysregulated genes and
significantly lower dysregulation of biological pathways compared to untreated patients, with particular improvement
indicated for nervous system functions. However a core of about 100 genes remained similarly dysregulated in both treated
and untreated patient brain tissues. These genes participate in adaptive immune responses, and in interferon, cell cycle, and
myelin pathways. Fluctuations of cellular gene expression in the brain correlated in Pearson’s formula analysis with plasma
but not brain virus burden. Our results define for the first time an aberrant genome-wide brain transcriptome of untreated
HAND and they suggest that antiretroviral treatment can be broadly effective in reducing pathophysiological changes in the
brain associated with HAND. Aberrantly expressed transcripts common to untreated and treated HAND may contribute to
neurocognitive changes defying ART.
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Introduction
HAND is a common complication of HIV-1 infection in the
nervous system presenting a varied spectrum of clinical manifes-
tations with cognitive, motor and behavioral symptoms. Currently
three conditions of increasing severity are recognized as compo-
nents of HAND: HIV-1-associated asymptomatic neurocognitive
impairment, HIV-1-associated mild neurocognitive disorders
(MND), and HIV-1-associated dementia (HIV-D or HAD) [1].
HAND remains prevalent in populations with access to highly
active ART, despite the efficacy of these therapies in controlling
viral load and ameliorating viral load-associated clinical and
neuroradiologic abnormalities [2–6]. By some accounts, up to
50% of HIV-1-infected individuals will develop some form of
HAND regardless of access to currently available ART [7–9].
Under ART, HAND has became milder, its course more
protracted and variable in symptoms, and it now overlaps with
aging processes and potentially with other neurodegenerative
diseases in AIDS patients [7,10,11]. The etiology of persistent
cognitive deficits in patients on ART remains unclear. Studies of
cerebrospinal fluid from individuals with HAND have sometimes
supported contradictory conclusions; in the absence of viral
replication, some authors observe associations among dementia,
abnormal neurometabolites, and inflammatory phenotypes; oth-
ers, with non-inflammatory states or markers of neurodegenera-
tion [12–16]. There have been limited studies of brain tissues from
treated patients with HAND to evaluate what biologic pathways
remain abnormally regulated under ART, with studies largely
focused on single cell types or molecules [17]. Comprehensive
analysis of the spectrum of molecular abnormalities in the brain
that may underlie HAND in the presence of ART has not yet been
undertaken.
PLoS Pathogens | www.plospathogens.org 1 September 2011 | Volume 7 | Issue 9 | e1002213Here we used functional genomics to conduct comparative
analysis of genome-wide gene expression profiles in brain tissues
from treated and untreated patients who died with HAND.
Functional genomics has been applied with success to identifica-
tion of complex molecular pathways in carcinogenesis and to
better detection, classification, and prognosis of some cancers [18–
23]. This approach has also been used extensively to investigate
the transcriptome correlates of HIV-1 infection in peripheral
tissues from HIV-1-infected patients including lymph nodes [24–
26], CD4
+ T cells [27,28], monocytes [29], B cells [30], and
gastrointestinal mucosa [31]. Some of these studies determined the
effects of ART on HIV-1 transcriptomes in patients, revealing
categories of treatment-responsive genes as well as aberrantly
expressed transcripts that may serve as targets for future therapies
[24,27–31]. In a related approach, a recent study evaluated gene
expression profiles of blood monocytes as a function of ART and
neuropsychological impairment of HIV-1-infected patients [32].
Interestingly in this case, there was no correlation between
changes in blood monocyte transcriptomes under treatment and
clinical HAND [32]. Generally, this research benefited from the
ability to serially sample peripheral tissues and individual cell types
in living individuals, allowing ongoing evaluation of treatment.
In contrast, analyses of human brain tissues by functional
genomics can only be conducted retrospectively in autopsy tissues
and are complicated by the multicellular interactions underlying
central nervous system diseases [33]. Nonetheless, large-scale,
cross-sectional gene expression profiling of brain tissues has
revealed potential pathogenic pathways in Alzheimer’s disease
(AD) [34,35], Parkinson’s disease [36,37], chronic schizophrenia
[38], multiple sclerosis [39], and viral encephalitis [40]. With
respect to HIV-1 infection in the brain, investigators reported
transcriptional changes in selected gene categories such as anion
channels in the frontal cortex of patients who died with HAND
[41,42]. Another group reported aberrant expression of genes
specific to HIV-1 encephalitis (HIVE) [43], established a
correlation between use of methamphetamine and up-regulation
of interferon genes in these patients [44], and investigated the role
of microRNA in gene regulation in HIV-1-infected brain [45]. To
our knowledge, these studies did not consider the effects of ART
on brain gene dysregulation in HAND.
The Manhattan HIV Brain Bank (MHBB; member of the
National NeuroAIDS Tissue Consortium) follows a cohort of
advanced-stage, HIV-1-infected individuals with a high prevalence
of well-characterized cognitive dysfunction; with entry to the
study, participants agree to be organ donors upon death. The
antiviral treatment status of study participants is monitored while
in the program. Thus, brain tissues obtained by this program
provide an opportunity to examine the potentially diverse
processes underlying HAND in the ART era. We report herein
the gene expression profiles of individuals with HAND focusing on
the impact of ART on these profiles.
Results
Effect of therapy on HIV-1 brain burdens
We assayed virus burden and cellular gene expression on
archived brain tissues from 15 HIV-1-infected patients with
HAND and six HIV-1-negative subjects with no neurological or
neuropathological abnormalities. Information for this study group
is summarized in Table 1 and Methods. All assays were performed
on parallel samples from deep white matter within the anterior
frontal lobe, an area implicated in HAND and HIV-1-associated
neuropathologies [46,47]. Custom consensus primers based on
sequences of HIV-1 amplified from the brain were used for
reliable measurement of HIV-1 in the brain by quantitative real-
time PCR (QPCR) (see Methods); the results were confirmed by
standard PCR and hybridization with a specific probe (Table 1
and Supplementary Figure S1). Pre-mortem plasma HIV-1
burdens are plotted for comparison (Supplementary Figure S1).
With the exception of patient 30015, the HIV-1 brain burdens in
untreated patients correlated with presentation of HIVE; on
average, these patients had about 180-fold more viral RNA per mg
total RNA than patients without HIVE. Patient 30015 had limited
HIVE pathology and no detectable virus in the brain (Table 1).
Patients on ART, both with and without HIVE, had lower virus
burdens in the brain than untreated patients, results consistent
with a previous study in a different cohort [48]. In patients with
HIVE the reduction was 50% and 95% at the DNA and RNA
levels respectively, while virus was undetectable in treated patients
without HIVE. Notably, there was no correlation between brain
and plasma viral loads and brain virus burdens were independent
of patient’s age, gender, ethnic background, or postmortem
interval.
Untreated HAND patients with dementia have similar
brain tissue transcriptomes irrespective of their HIVE
histopathology and virus burdens
Global gene expression profiles of patient brain tissues were
determined on Affymetrix GeneChip Array Human Genome
U133 Plus 2.0 Arrays. Three independent array experiments were
performed, each comprising a subset of HIV-1-positive samples
and controls, with most samples tested either in duplicates or
repeated in independent runs and some samples tested three times.
Replicate gene sets of the same samples were averaged, yielding 21
final brain tissue datasets for 21 subjects. Preliminary hierarchical
cluster analysis of complete datasets from HAND patients
indicated that the primary biological variable in clustering of
these datasets was whether or not patients were on ART at the
time of death (not shown). Interestingly, this analysis also indicated
that brain transcriptomes from untreated patients with HIVE did
not cluster independently of non-HIVE transcriptomes (Figure 1A),
suggesting that they are statistically similar across their entire
Author Summary
HAND is a common complication of HIV-1 infection in the
nervous system presenting a varied spectrum of clinical
manifestations with cognitive, motor and behavioral
symptoms. Introduction of ART has greatly reduced
morbidity and mortality in HIV-1 infection; however HAND
persists and its overall prevalence appears to have
increased despite treatment. The effects of the treatment
on neurological disease are not well understood. Here, we
used genomic analysis to compare gene expression
profiles in brain tissues from treated and untreated
patients who died with HAND. We identified a large
number of genes and biological pathways dysregulated in
untreated HAND compared with uninfected controls. ART
appears to be effective in mitigating aberrant gene
expression in brain tissues of patients with HAND but a
fraction of genes remained dysregulated under ART and
the patients continued to manifest HAND in the last
evaluation prior to death. Our study provides new insights
into the molecular changes in brain tissues of patients with
HAND and the effect of the treatment on brain tran-
scriptome. The identification of aberrantly expressed
genes common to untreated and treated HAND may
contribute to understand the neurocognitive impairment
observed in patients under ART.
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HIVE had on average higher brain virus burdens than patients
without HIVE (Table 1 and Supplementary Figure S1) and HIV-1
infection is known to induce cellular gene expression [49]. To
confirm findings of cluster analysis we performed global gene set
analysis using GAzer software [50] to identify biological pathways
that were most significantly altered in HIVE positive and negative
groups compared to uninfected controls (Figure 1B). GAzer
employs parametric analysis of sets of co-regulated genes across
complete microarray datasets, independent of arbitrary fold
change (FC) value limits, thus increasing statistical power of
detection of biological differences between datasets [50,51].
Figure 1B depicts the eight most altered pathways in HAND
and HAND/HIVE datasets versus controls and Supplementary
Table S1 lists all aberrant pathways and detailed statistics of
GAzer analysis including Z-score, p-and q-values, and Bonferroni
correction value. Consistent with previous array studies in HIVE
patients [43,44], datasets of patients with HIVE showed greater
dysregulation of immune responses and endogenous antigen
presentation pathways than those without HIVE (Figure 1B),
possibly reflecting effects of high virus burdens in the brain in
untreated HIVE (Table 1). However, the two HAND patient
groups were generally similar with respect to the ranking and
extent of change (indicated by all four statistical measures) of the
majority of altered gene sets (Figure 1B and Supplementary Table
S1). Because of their overall similarities in both cluster and gene set
analyses, we chose to pool microarray datasets from HAND
patients with and without encephalitis for analysis of antiviral drug
effects.
Patients with HAND on antiretroviral therapy have many
fewer and milder gene expression changes in the brain
than untreated patients
Seven of the 15 patients in our cohort were treated using
different antiretroviral drug combinations (Table 1) enabling
investigation of the extent of HIV-1-induced changes in the brain
and potential differences between treated and untreated patients at
the level of brain transcriptomes. Patient microarray datasets were
pooled separately into untreated (HAND, n=8) and treated
(ART, n=7) groups and each group was compared to the
uninfected control pool C (n=6). We used a cut-off of 1.5 FC and
p-value,0.05 to identify significantly dysregulated genes. For
Table 1. Study subject information and HIV burdens in different compartments.
Brain vl
Pid Code Category ART PMI Age Sex R Risk CD4
Plasma
vl
CSF
vl
DNA
(copies)
RNA
(copies)
Brain
Pathology ART
adherence
mhbb531 C1 HIV neg none 22 44 M W na na un un normal
mhbb551 C2 HIV neg none 24 30 F H na na un un normal
mhbb567 C3 HIV neg none 19 63 M H na na un un normal
mhbb601 C4 HIV neg none 16.5 58 F H na na un un normal
mhbb594 C5 HIV neg none 24 57 F W na na un un normal
mhbb588 C6 HIV neg none 18.5 21 M H na na un un normal
mhbb500 HAND 1 HAND none 48 47 M W Hom-sx 20 210000 na 115468 689556 HIVE
mhbb537 HAND 2 HAND none 27 45 F B IVDU 6 na na 58001 902832 HIVE
10017 HAND 3 HAND none 4 44 M W IVDU 7 389120 .750000 234372 762888 HIVE
10070 HAND 4 HAND none 4 58 M B Het-sx 1 750000 .750000 471248 10689754 HIVE
30015 HAND 5 HAND none 6 43 M B Hom-sx 10 48520 134 un un HIVE*
10119 HAND 6 HAND none 6 33 M B Hom-sx 1 312240 ,50 l.pos un minimal
30013 HAND 7 HAND none 6 30 M B Het-sx 8 104300 ,50 l.pos 62826 ischemia
10011 HAND 8 HAND none 8.5 44 M H Hom-sx 16 162642 na un 702 normal
mhbb509 ART1 HAND d4t,nor,cri 12 46 M W Hom-sx 203 80000 na 262933 2516 HIVE na
10133 ART2 HAND d4t,kal,nev 7.5 48 M W Hom-sx 3 173921 na 64511 448390 HIVE 80
10103 ART3 HAND tri,kal,ten 6 40 M H Het-sx 15 750000 .750000 3789 854 HIVE 50
10063 ART4 HAND d4t,aba,ten 5 51 M H IVDU 136 65 ,50 un un minimal 90
10001 ART5 HAND d4t,3tc,kal 4.5 64 F B IVDU 72 359 ,50 un un minimal 60
10015 ART6 HAND d4t,3tc,efa 20 33 M W Hom-sx 66 176800 na un un minimal na
20024 ART7 HAND d4t,3tc,aba 4 62 M W IVDU 20 un 501 un un normal 95
Brain tissues and study subject information were obtained from the Manhattan HIV Brain Bank (MHBB) as described in Methods. Pid: subject I.D. at MHBB. Category
abbreviation: HAND: HIV-Associated Neurocognitive Disorder. ART: antiretroviral treatment. ART drug abbreviations: nor: norvir; cri: crixivan; kal: kaletra; nev: nevirapine;
tri: trizivir; ten: tenofovir; aba: abacavir; efa: efavirenz; 3tc: epivir, lamivudine; d4t: stavudine. The duration of the listed ART regimen prior to death while in the MHBB
program was (in months): ART1 (5), ART2 (4), ART3 (6), ART4 (36), ART5 (24), ART6 (36), ART7 (3). PMI: post-mortem interval. R: race (W: white; H: hispanic; B: black); Risk:
IVDU: intravenous drug use; Het-sx: heterosexual; Hom-sx: homosexual. CD4: number of CD4 positive T cells per mm
3 and vl, virus loads in plasma and CSF in RNA
copies per mL were provided by MHBB with other patient information. Brain vl was determined in this work by real-time PCR and expressed as viral DNA copies per
500,000 cells, the latter determined by beta-globin gene content, and viral RNA copies per 1 mg RNA; virus detection was confirmed by standard PCR and Southern
hybridization with a specific probe; un: undetectable by QPCR or standard PCR; l.pos: low-positive by standard PCR; na: data not available. Brain pathology: see Methods
for detailed definitions.
doi:10.1371/journal.ppat.1002213.t001
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low adherence subjects ART3 and ART5. The complete lists of
FC values and accompanying statistics for HAND, ART, and
ARTa are provided in Supplementary Tables S2 and S3. Overall,
we identified 2073 dysregulated transcripts in the untreated
HAND group and 333 and 145 transcripts in the ART and ARTa
groups, respectively (Table S2). The Venn diagram in Figure 2A
depicts the number of genes dysregulated in brain tissues of
untreated and treated patients with HAND and the overlap in the
dysregulated genes among the three groups tested. Excluding
multiple probes for the same gene and transcripts of undefined
function at the time of this writing, the HAND group had 1470
genes with significantly altered expression compared to 260 in
ART and 107 in ARTa (Figure 2A, Supplementary Tables S2 and
S3). About two-thirds of dysregulated genes (947) in untreated
patients were up-regulated and 95 of these had FC values of $3.0
and p=10
22–10
27, among down-regulated genes, 58 had FC of
#23.0 and p of 10
22–10
24, suggesting that HIV-1 infection
profoundly alters the brain transcriptome in untreated patients
with HAND and indicating significant conformity of molecular
profiles of disease in this cohort. In treated patients, down-
modulated genes predominated, the FC values ranged from 3.95
to 1.5 for up-regulated genes and from 21.5 to 22.87 for down-
regulated genes, and p-values were 5610
22–7.3610
25 (Supple-
mentary Tables S2 and S3), indicating less uniformity of brain
gene expression in this group. These results indicate marked
differences between aberrant brain transcriptome profiles of
untreated and treated patients, the latter showing 6–14-fold
(depending on treatment compliance) fewer dysregulated genes
with generally lesser dysregulation of expression than in untreated
patients.
To confirm this observation we conducted gene ontology
analysis using GAzer to examine cellular processes affected by
HIV-1 infection in the brain in our patient groups. Altered gene
sets (biological pathways) were identified by comparing each
patient group to HIV-1-negative controls; Supplementary Table
S4 lists these pathways for HAND, ART, and ARTa in the order
of their significance as determined by the Z-score, p and q values,
and Bonferroni statistics [50,51]. Figure 2B shows the eight most
dysregulated biological pathways in the HAND datasets, display-
ing the extent of dysregulation in the same pathways in ART and
ARTa datasets. Up-regulated pathways in untreated HAND
patients included immune responses, inflammation, response to
virus, and complement activation while synaptic transmission,
neurogenesis, ion transport, cell adhesion, and signal transduction
were down-regulated. The statistical significance for the eight
major pathway changes reached Z-scores of 6–14 and p, q and
Bonferroni values of $10
28 (Figure 2B and Supplementary Table
S4). In contrast, samples from treated patients showed either fewer
significantly altered pathways (ART and ARTa panels in
Figure 2B) or lesser extent of dysregulation of the remaining
pathways displayed (e.g., the ART panel in Figure 2B). The extent
and kind of changes in gene ontology processes in the treatment
compliant ARTa group were limited compared to changes seen in
untreated patients: of the 8 most up-regulated HAND pathways
only endogenous antigen presentation and processing were also
up-regulated in ARTa with Z-scores less than 2.5, low significance
compared to other pathways (p=0.018 and 0.026, respectively),
and no down-regulated gene sets in these categories were
identified (Figure 2B and Supplementary Table S4). Notably,
some pathways that were significantly down-regulated in HAND
were significantly up-regulated in ARTa including neurotransmit-
ter secretion (Z=4.26; p=2610
25) and synaptic transmission
(Z=2.9; p=0.0037) (Supplementary Table S4).
Dysregulation of selected genes detected by microarrays was
confirmed in adjacent tissues by QPCR. Genes were chosen by
previous demonstration of their link to HAND [52–56].
Representative gene expression values are shown in Figure 2C
and the complete list is provided in Supplementary Table S5.
Consistent with microarray data, brain tissues from untreated
patients showed significant up-regulation of complement component 3
(C3), macrophage antigen CD68 (CD68), and protein-tyrosine phosphatase
receptor-type C PTPRC (also known as CD45R); and down-
regulation of neuronal cyclin-dependent kinase 5, regulatory subunit 2
(CDK5R2) (only significant for p39), neuronal marker microtubule-
associate protein 2 (MAP2) and the SNARE protein complexin 1
(CPLX1), compared to brains of patients on ART. As also noted in
other studies [57], confirmatory QPCR analyses generally yielded
higher FC results than parallel microarray analyses (Supplemen-
tary Table S5). Four of the changes in gene expression in the brain
were also tested at the protein level by immunohistochemistry
(Figure 2D). We observed increased expression of CD68, C3c and
CD45R proteins in untreated HAND compared to uninfected
control tissue, and an amelioration of the protein dysregulation in
patients with HAND on ART. MAP2 protein was down-regulated
in HAND brains compared with brains from uninfected subjects,
and it was partially restored in patients under treatment for HIV-1
infection. Taken together, our findings parallel recent reports of
the effects of ART on gene expression in peripheral tissues
[24,27,29] in that treatment of HIV-1 infection by ART is also
Figure 1. Similarity of brain transcriptomes of untreated HAND patients with and without encephalitis. A. Using Affymetrix microarrays
we evaluated gene expression in brain tissue. Normalized data from HAND patients with or without encephalitis were analyzed by Hierarchical
Clustering using Genesis software. B. Gene set analysis was conducted by GAzer software to identify biological pathways most significantly up-
regulated (right panel) or down-regulated (left panel) in untreated HAND without or with encephalitis (HAND/HIVE) vs. uninfected controls.
doi:10.1371/journal.ppat.1002213.g001
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PLoS Pathogens | www.plospathogens.org 4 September 2011 | Volume 7 | Issue 9 | e1002213Figure 2. The pattern of changes in brain cell gene expression relative to uninfected subjects differs significantly between
untreated HAND patients and HAND patients treated with ART. A. The Venn diagram displays the number and overlap of transcripts
differentially expressed relative to uninfected subjects from HAND, ART, and HAND patients excluding low adherence patients ART3 and ART5 (ARTa).
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ulation of gene expression in brain tissues. Treatment adherence
further reduces the number of genes and biological pathways
affected.
Gene expression profiles from treated HAND patients
cluster with profiles from HIV-1-negative controls
In the next level of analysis, we conducted unsupervised
hierarchical clustering for 2073 dysregulated transcripts implicated
in HAND (Figure 2A and Supplementary Table S2) to visualize
and group individual gene expression profiles from all 21 subjects
in this study (Figure 3A). We used normalized Robust Microarray
Average (RMA) values from duplicate samples for each subject for
greater statistical power (Methods). Three main clusters of subjects
were identified. With the exception of HAND5, untreated HAND
patients clustered as one group (cluster 2 in Figure 3A) distinct
from the other two clusters. ART-treated HAND patients
clustered with uninfected controls in two co-mingled clusters,
cluster 1 containing subjects C1, C2, C3 and ART1 and cluster 3
including subjects C4, C5, C6, ART2, ART3, ART4, ART5,
ART6, and the remaining untreated HAND5. Compared to
cluster 3, cluster 1 was more phylogenetically distant from
untreated HAND, but overall clusters 1 and 3, separately or
combined, were significantly different from cluster 2. The t-test
values computed using RMA values for all transcripts in cluster 1
vs. cluster 2, cluster 3 vs. cluster 2, and cluster 1+cluster 3 vs.
cluster 2 were 1610
2221, 7.8610
225, and 1.96610
224, respec-
tively. These results demonstrate that for the 2073 transcripts
tested, gene expression in brain tissues of patients on ART tends to
resemble that of uninfected subjects, indicating that ART is
associated with a profound reduction in the extent of dysregulation
of HAND-related genes in the brain. These results also suggest
that the differences related to HIV-1 disease (and treatment)
override potential differences resulting from genetic heterogeneity
of individual donors.
The statistical similarity of ART transcriptomes with HIV-1-
negative controls with respect to presumptive HIV-1-impacted
genes (Figure 3A) prompted us to directly compare gene
expression changes of ART brain tissue to expression in HAND
brain tissue, without filtering microarray results through HIV-1-
negative controls. This analysis inquires whether control of HIV-1
replication by ART removed viral perturbations to cellular gene
expression in the brain, analogous to longitudinal studies of
peripheral tissues from HIV-1-infected subjects pre and post-ART
[24] which are not feasible for the brain. Using normalized RMA
datasets for over 54,000 transcripts detected by the U133 chipset,
we compared 7 treated patients to 8 untreated patients delimiting
the results by FC of 1.5 and t-test value of 0.05; the complete list
these differentially expressed transcripts is shown in Supplemen-
tary Table S6. In calculating the ratio of gene expression in ART
to HAND, positive FC values in ART indicate an association of
increased gene expression with treatment and negative FC
indicate reduced cellular gene expression associated with treat-
ment. Overall, we identified 640 significantly up-regulated and
276 down-regulated genes in this analysis (Supplementary Table
S6). Samples from patients with treated HAND show increased
expression (relative to untreated HAND) of many genes involved
in neuronal functions including synaptoporin (SYNPR, FC 6.55 and
p=6.5610
24), neurofilament, light polypeptide (NFEL, FC 6.15,
p=4.6610
24), and synaptotagmin IV (SYT4, FC 4.16, p=
5.8610
24) compared to samples from untreated patients.
Conversely, genes involved in immune activation including
CD74 antigen (CD74, FC 22.49, p-0.013), complement component 1,
q subcomponent, C chain (C1QC, FC 22.47, p=0.022), and interferon-
induced protein with tetratricopeptide repeats 2 (IFIT2, FC 22.35,
p=0.007) were reduced in expression in treated HAND patient
samples relative to samples from untreated patients. For reference,
Supplementary Table S6 also lists respective ART microarray
data normalized to HIV-1-negative controls. Notably, all but 7 of
the genes in treated patients that increased in expression relative to
untreated HAND were unchanged in the ART/HIV-negative
control comparison (Supplementary Table S6), suggesting that
treated patients express these genes at normal (control) levels.
Similar normalization of expression (272 out of 276) was found for
genes that were down-modulated in ART versus HAND.
To put these findings in the context of the biological pathways
potentially affected by ART, we employed GAzer to compare the
complete ART microarray datasets to those from HAND.
Figure 3B depicts 16 biological processes that were most
significantly changed in ART relative to HAND and Supplemen-
tary Table S7 provides complete statistics for this analysis. Twelve
up-regulated processes in treated versus untreated HAND, with Z-
scores ranging from 9.54 to 5.02, were related to neuronal
function and repair. The down-modulated pathways included, in
decreasing order of significance, immune responses, inflammatory
responses, apoptosis, and responses to stress. These results suggest
that ART reverses many dysfunctional processes of untreated
HAND represented in gene ontology analysis. To provide an
alternative view of the extensive up-regulation of cellular processes
in ART relative to HAND, up-regulated genes with p-values of
#0.01 included in Supplementary Table S6 were analyzed by
STRING to identify predicted gene interaction networks
(Figure 4). In this analysis ART was associated with improved
synaptic transmission including synaptic vesicle system, nervous
system development including cytoskeleton associated proteins,
and GABA neurotransmission networks. These findings strongly
suggest that by reducing HIV-1 replication, ART also reduces
triggers to aberrant gene expression in the brain.
Identification of genes that remain significantly
dysregulated in the brain despite treatment
The HAND patients in this study share cognitive dysfunction
whether they were untreated or treated with ART (Table 1). To
begin to identify transcripts that may contribute to HAND
development or persistence despite ART, we used t-test to
compare significantly changed genes in untreated (Supplementary
Table S2) and treated (Supplementary Table S3) patients with
HAND; a gene whose expression was not significantly different in
the HAND versus ART comparison (p.0.05) was considered
similarly dysregulated in both groups of patients relative to
uninfected subjects. We have identified 43 such up-regulated and
42 down-regulated genes; they are listed grouped into biological
B. GAzer was employed to identify the eight most dysregulated biological pathways relative to uninfected subjects in the HAND dataset and the
extent of change in the same pathways in ART and ARTa datasets are shown for comparison with Z-scores plotted for the significantly up-regulated
(right panel) and down-regulated (left panel) pathways. C. QPCR analysis of gene expression in HAND and ARTa patients plotting fold change of
expression uninfected subjects. Asterisks represent p-value,0.05 in t-test analysis, asterisks over column indicate comparison to values from
uninfected subjects, asterisks between columns represent their comparison. D. Immunostaining and quantitation of selected proteins in brain tissue
of uninfected subjects (C), HAND and ART patients.
doi:10.1371/journal.ppat.1002213.g002
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PLoS Pathogens | www.plospathogens.org 6 September 2011 | Volume 7 | Issue 9 | e1002213Figure 3. Extent and kind of differences in brain cell gene expression in untreated HAND patients and HAND patients receiving
ART. A. Selecting the transcripts differentially expressed in brain tissue from HAND patients relative to uninfected subjects, hierarchical cluster
analysis was performed on extent of expression from all subjects using Genesis software. Red represents up-regulation, green represents down-
regulation. B. Gene ontology analysis of ART dataset vs. HAND dataset was performed using GAzer software. The upper panel shows pathways
elevated in ART and the lower panel shows pathways suppressed in ART relative to HAND brain samples.
doi:10.1371/journal.ppat.1002213.g003
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expression statistics are listed in Figure 5A, and their heatmap
expression profiles in all subjects in this study are shown in
Figure 5B. Considering functional characterization, genes related
to immune responses were up-regulated in both HAND and ART
samples including complement receptor 1 (CR1), chemokine, CXC motif,
ligand 2 (CXCL2), major histocompatibility complex, class II HLA-
DQB1 and interferon-mediated antiviral responses including
interferon-induced protein with tetratricopeptide repeats 1 (IFIT1); interfer-
on-induced protein 44 (IFI44); myxovirus resistance 1 (MX1); 29,59-
oligoadenylate synthetase 1 (OAS1), and signal transducer and activator of
transcription 1 (STAT1). Cell cycle pathway was dysregulated in
both treated and untreated HAND patients, with some sets of
genes up-regulated and others down-regulated (Figure 5A and 5B).
Over-expression of selected transcripts in interferon or chemokine
pathways in both HAND and ART brain samples was confirmed
by real-time PCR (Figure 5C), over-expression of HLA Class II
alleles and proliferating cell nuclear antigen (PCNA) was also
demonstrated by immunohistochemistry (Figure 5D). Of particu-
lar interest, common down-regulated genes in treated and
untreated patients with HAND included myelin-related genes
myelin-associated oligodendrocyte basic protein (MOBP), myelin transcription
factor 1 (MYT1) and myelin basic protein (MBP). Down-regulation of
MOBP and MYT1 was confirmed by real-time PCR, with the
MYT1 gene being particularly suppressed in the ART group
(FC=238.38, p=1610
25) (Supplementary Table S5). This result
is consistent with histopathological detection of myelin pallor in
autopsy brain tissues from some patients with HAND [58,59],
although other explanations also exist [60].
Correlation of gene expression changes in the brain and
HIV-1 load in different compartments
Pearson’s formula was applied to determine the correlation of
the level of expression of each transcript with HIV-1 load in
plasma, cerebrospinal fluid (CSF) and brain. Examples of genes
correlating positively with plasma viral load are shown in
Figure 6A, including histocompatibility loci HLA-B-G and F,
interferon-gamma-inducible protein 30 (IFI30), OAS1, and Cathepsin S
(CTSS). Transcripts with a positive (.0.5) or negative (,20.5)
correlation with viral load were analyzed using the gene ontology
software Expression Analysis Significance Explorer (EASE) to
identify the pathways that correlated most with viral load
(Figure 6B). Pathways positively correlated with viral load were
similar in the three compartments (brain, CSF, plasma), including
several immune activation responses. The main difference among
Figure 4. Predicted interaction networks of brain cell genes significantly downmodulated in untreated HAND and expressed at
close to control levels in HAND patients under ART. The interactions between genes were identified using STRING software with each type of
interaction distinguished by color. The most significantly regulated pathways identified in this analysis are synaptic transmission, nervous system
development and GABA neurotransmission pathway.
doi:10.1371/journal.ppat.1002213.g004
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changes, as represented by the EASE score. All the pathways
implicated in immune response correlated better with plasma viral
load than with brain viral load. Even though CSF data were
available for only 9 of the 15 infected patients, the positive
correlations for CSF were higher than those for brain, although
less strong than those observed for plasma. The categories of
antigen presentation and processing were correlated only with
viral load in plasma. Pathways down-regulated in correlation with
viral load differed depending on the compartment tested. No
biological pathway correlated negatively with brain viral load.
Pathways negatively correlated with plasma viral load included
synaptic transmission, cell communication, transmission of nerve
impulse, organogenesis and neurogenesis. A wide variety of
metabolic pathways negatively correlated with CSF viral load.
Overall, grouping genes engaged in similar biological functions
indicates that gene groups induced in the brain correlated best
with virus burden in the periphery and that virus burden in the
brain, unlike viral load in plasma or CSF, was uncorrelated to
suppression of expression of any gene group.
Discussion
We employed functional genomics to investigate the potential
effects of antiretroviral treatment on brain pathophysiology in a
cohort of patients who died with HAND. Our results suggest that
ART profoundly, but not completely, alleviates aberrant gene
expression in brain tissues of these patients. These findings may
shed light on the molecular basis of HAND persistence despite
treatment. Several points should be made about this work.
Microarray profiles of HAND
The foundation of this work is a new comprehensive database of
global gene expression profiles in brain tissues of patients with
HAND. The profiles described here complement published
datasets from previous array studies in HAND [41–44] with
important differences. For the first time in this disease, we
analyzed brain transcriptomes on the basis of the antiretroviral
treatment of patients, revealing two distinct, largely non-
overlapping groups of aggregate gene expression profiles termed
ART and untreated HAND. The ART and untreated HAND
profiles also formed separate clusters in unsupervised hierarchical
cluster analysis [61] of individual patient datasets, confirming that
they are phylogenetically distant from each other based on a large
sets of aberrantly expressed genes used in this analysis (Figure 3A).
Importantly, the hierarchical clustering distinction between
treated and untreated patients was statistically more prominent
than potential distinctions in gene expression related to other
patient characteristics in our cohort including HIVE and
intravenous drug use (Figure 3A and Supplementary Figure S2).
Therefore, in most analyses in this work we considered datasets
from patients with and without HIVE as one disease category,
stratified only on the basis of ART. These results suggest that
ART, through effects on HIV-1-associated changes in cellular
gene expression [27,62,63], is one of the key biological variables
governing the extent and pattern of gene dysregulation in
molecular profiles of HIV-1 brain disease.
Another important difference with previous HAND array
studies concerns the histological regions of the brain tested. We
evaluated frontal deep white matter, whereas most of the previous
studies focused on the neighboring cortical gray matter [41–44] or
small gene sets in both brain regions [41]. White matter is the
primary site of HIV-1 infection and HIV-1-associated neuropa-
thologies [46,47] and frontal cortex is one of the sites of synaptic
and dendritic damage consequent to this infection [64,65].
Transcriptomes from these two areas reflect different regional
physiologies and therefore different aspects of HIV-1 neuropatho-
genesis. With these caveats, a meta-analysis summarized in
Supplementary Table S9 identified a small number of genes
involved in interferon-related responses (IFIT1, IFITM1, IFI44,
MX1), synaptic functions (SYN1, SYN2, GABRG2, MAP2), and
cell cycle (CDC42, CDK5R1, R2) that were dysregulated in
common in the present and previously published HAND datasets.
These genes and biological pathways may represent features of
HIV-1-associated neuropathogenesis common to white and gray
matter.
Brain tissues of untreated patients with HIV-1 dementia
show extensive dysregulation of gene expression
independent of presence of HIVE
During the last twenty years, individual inflammatory and
neurodegenerative mediators in HAND brains were demonstrated
by immunocytochemistry, in situ hybridization, and other methods
(reviewed in [66–69]). The bulk of this work was conducted with
brain tissues from untreated patients, as brain autopsies after
introduction of ART have become less frequent [70]. Consistent
with these observations, the untreated HAND profile defined here
reveals a broad and extensive dysregulation of cellular gene
expression in brain tissues, with 1470 HAND-associated aber-
rantly expressed genes, up-regulation of immune activation,
antiviral responses, and inflammation, and down-modulation of
neuronal functions, neuronal repair, and cell cycle. It should be
noted that our untreated HAND profile included transcriptomes
from patients with and without HIVE (Figure 2 and 3). HIVE is a
characteristic histopathology associated with high HIV-1 burdens
in the brain [71,72], and previous array studies documented
differentially expressed transcripts and biological pathways
potentially attributable to the extensive infection in the brain
[43–45,73]. We confirmed some of these differences in our
untreated group with and without HIVE in gene ontology analysis
but it is noteworthy that they differed mainly in the degree of
dysregulation and not the biological pathways affected (Figure 1).
Thus, at the level of a transcriptome analysis, the altered
expression of some transcripts attributed to high HIV-1 burdens
in HIVE [43,44] contributes to but does not change the overall
statistical characteristics of the molecular phenotype of HAND.
Our results are consistent with reports of limited correlation
between clinical manifestations of HAND and HIVE histopathol-
ogy [58,74,75]. Rather, untreated HAND appears to correlate
better with presence of inflammatory mediators and diffusely
activated macrophages and microglial cells in the brain than with
virus burdens in the tissue per se [17,58,75–78].
Independent microarray studies in other patient populations are
needed to determine whether these gene expression profiles are
Figure 5. Common dysregulated genes in brain tissues of treated and untreated HAD patients. A. Selected genes significantly up or
down-regulated in HAND or ART patients compared to uninfected subjects are tabulated (FC: Fold-change, pv: t-test p-value). B. Heatmap
representation of significantly dysregulated genes in both HAND and ART datasets relative to uninfected subjects. C. QPCR analysis of expression of
selected genes in HAND and ART patients relative to uninfected subjects. D. Immunostaining and quantitation of selected proteins in brain tissue.
doi:10.1371/journal.ppat.1002213.g005
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Examples of individual genes whose expression positively correlates with plasma virus load (r
2: Coefficient of determination, PC: Pearson correlation).
B. The upper panel shows positive correlations and the lower panel shows negative correlations with virus load (vl) in plasma, CSF, or brain
respectively and gene expression in the brain. Genes that correlated positively and highly with virus load were analyzed using EASE software also
negative correlations. The EASE score represent the significance of the regulated pathways.
doi:10.1371/journal.ppat.1002213.g006
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profiles of disease can serve as a platform for verification of results
obtained in studies of individual physiological processes [33,79,80]
and as a tool for discovery of new ones. In this context, a number
of ‘‘novel’’ (i.e., relatively new to the HAND literature)
dysregulated genes in our untreated HAND database may shed
light on the process of HAND pathogenesis and merit further
investigation. For example, transcripts encoding apolipoprotein C-I
and C-II (APOC-I and APOC-II) were among the most up-
regulated in the untreated HAND dataset, with FC of 5.71
(p=9.7610
25) and 3.35 (p=0.009), respectively (Supplementary
Table S2). Dysregulation of lipid metabolism linked to APOE
polymorphism is a marker of AD [81] and was indicated in HIV-1
dementia [82,83]. While we could not find reports on APOC-I in
HAND, this lipoprotein was found in association with beta-
amyloid plaques in AD brains and expression of human APOC-I
allele in native APOC-I null mice was shown to impair learning
and memory [84]. Conversely, hemoglobin a-2 and hemoglobin b
(HBA-2 and HBB) were among the most down-regulated
transcripts in our untreated HAND dataset (FC of 25.31 and
24.22; Supplementary Tables S2 and S5). Neuronal hemoglobins
are members of the globin superfamily which are predominantly
expressed in neurons and may play an important role in
neuroprotection [85]. Consistent with our findings, expression of
neuronal hemoglobin is reduced or absent in disease affected brain
regions in patients with several neurodegenerative conditions
including AD and Parkinson’s disease [86].
ART efficiently mitigates aberrant gene expression in
brain tissues of patients with HAND
The major finding of this work is the profound difference
between the extensive global gene dysregulation observed in brain
tissues of untreated patients with HAND and muted gene changes
in their treated counterparts. The magnitude of ART effects in the
brain suggested by our results was surprising given the limited
clinical outcomes of ART on HAND [7,87], including in the
cohort evaluated here (Table 1), and variable findings in the CSF
of treated patients [12–16]. The ART effects on the brain were
inferred because we could not test brain RNA in the same
individuals before and after initiation of therapy, as is possible in
microarray studies with peripheral tissues [24,27,29,31]. However,
the overall effects of ART on altered gene expression were
remarkably similar in the periphery and brain. This was evident in
markedly fewer dysregulated genes in treated compared to
untreated patients, in our case 253 versus 1470; and in a global
shift in gene expression patterns from aberrant in the absence of
treatment to muted dysregulation under treatment, for example in
peripheral CD4
+ T cells [27,29], lymphoid tissue [26], and brain
here (Figure 3A). Importantly, both in the CD4
+ T lymphocyte
study [27] and in the present work, gene expression profiles of
treated patients were statistically similar to those of HIV-1-
negative controls, suggesting a trend toward normalization of gene
expression under ART. We confirmed this trend for selected gene
products in the present work by real-time PCR and immunocy-
tochemistry (Figure 2). These results suggest that ART regimens,
which generally include at least one brain penetrant antiviral
compound (Table 1), are similarly effective in mitigating global
molecular changes in the brain and in peripheral tissues.
We noted two reciprocal effects of ART on gene dysregulation
in brain tissues illuminating the systemic and brain-specific aspects
of HAND pathogenesis. One is a significant and broad
moderation of up-regulated genes linked to HIV-1 induced
antiviral and inflammatory responses thought to drive HAND
pathogenesis, including interferon-related ISG15 and IFIT3,
macrophage markers CD68, CD163, and CD14, and chemokines
and chemokine receptors CCL8, CCR1, and CXCR4 [67–69]
(Figure 2 and 3). Interestingly, this effect of ART was common to
diverse tissues examined by microarrays including brain (this
study) and CD4
+ T cells, macrophages, lymph nodes, and
intestinal mucosa tested by others [24,27,29,31], and thus it likely
represents a system-wide response to suppression of HIV-1
replication. Although gene ontology pathways containing these
genes in patients under ART were still up-regulated compared to
controls (Figure 2B and Figure 5), our results suggest that ART
can alleviate a surprisingly large number of deleterious responses
in the brain that have been linked previously to HIV-1 infection in
model systems [88]. This causal link is further strengthened by an
apparent correlation in this work between treatment compliance
and extent of gene dysregulation in the brain (Figure 2).
The other effect of ART in the brain we observed was specific to
the nervous system and it involved normalization of a large
number of down-regulated genes and biological pathways linked
to nervous system functions and by extension to neurocognitive
disease. For example, the bioinformatics tool STRING [89]
identified nervous system development, synaptic transmission, and
GABA-neurotransmission pathway as the three major predicted
interaction networks of genes that approached normal expression
in treated patients (Figure 4). On a smaller scale, our confirmatory
tests showed that products such as MAP2 and complexin-1 (CPLX1)
were significantly down-regulated in untreated patients at RNA
and protein levels and they were expressed at control-like levels in
tissues from treated patients (Figure 2). It is conceivable that
restoration of normal expression of at least some of these genes
under ART would restore some aspects of normal brain
physiology [7]. Although treated patients in our cohort still
manifested HAND prior to death, our results suggest that they
may have already shifted to a milder molecular profile in the brain
that had more in common with HIV-1-negative controls than
untreated patients.
Of interest, the global changes in brain cell gene expression seen
by microarrays correlated positively with plasma but not brain
virus burdens (Figure 6). This association may be analogous to the
clustering of brain transcriptomes independently of encephalitis
and brain HIV-1 burden by commonly dysregulated biological
pathways. In any case, the single measurement of brain virus
burden at autopsy may not capture the chronic insult to brain
function suffered by patients living years with HIV-1 infection,
albeit with some control exerted by ART.
Genes dysregulated in common under ART and in
untreated HAND
Perhaps the most intriguing contribution of the present array
analysis lies in the ability to discern patterns of abnormality that
persist in cognitively-impaired patients who are on central nervous
system penetrant ART, and to distinguish these patterns from
HAND in the untreated state. In the bioinformatics sense, we used
ART as a biological filter to reduce the overall gene expression
disturbance in brain transcriptomes of patients with HAND and
through that determine whether continuing dysregulation of gene
expression could play a role in continuing brain disease. The
results indicate that continuing up-regulation of innate and
adaptive immune responses are an important part of brain
abnormalities in ART-treated dementia. Over-expression of Class
II MHC in the brain persists despite therapy in our study; it has
been associated with many neurodegenerative diseases [90].
Defects in myelin metabolism, shown for HAND at the gene
expression level here and indicated previously by neuropatholog-
ical observation of myelin pallor in brains of patients with HAD
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[38,91]. Activation of interferon-related genes often found in
symptomatic HIV-1 infection may underlie abnormalities in cell
function [28]. Such changes, coupled with cell cycle perturbations,
may support emerging magnetic resonance spectroscopy studies
that have demonstrated persistent white matter inflammation in
patients with HIV-1-related cognitive impairment [92]. However,
it is unclear what particular aspects of immune activation or
response are relevant to nervous system dysfunction, and how to
distinguish deleterious gene products from those that may function
in a neuroprotective manner. In simian immunodeficiency virus
infection, innate immunity, IL-6, and interferon responses are
important elements in brain viral control [56,93], but in a recent
study expression of interferon-a in the brain was conclusively
linked to neuronal dysfunction in a mouse model of HIVE [94].
Careful analysis of individual genes identified here may begin to
clarify the mechanism of HAND persistence under treatment.
Materials and Methods
Ethics statement
Human brain samples and clinical data were obtained from the
Manhattan HIV Brain Bank (MHBB), a member of the National
NeuroAIDS Tissue Consortium, under an Institutional Review
Board-approved protocol at the Mount Sinai School of Medicine.
Written informed consent was obtained from all subjects in this
study or their primary next-of-kin. HIV-1 and gene expression
analyses were conducted on de-identified brain samples under an
‘‘exempt’’ status approved by an Institutional Review Board of St.
Luke’s-Roosevelt Hospital Center.
Study subjects and brain regions used for analysis
Study subject information is listed in Table 1. Fifteen HIV-1-
positive subjects used in this study were chosen on the basis of
having HAND and the presence or absence of HIVE as
determined by neuromedical or neuropsychological evaluation
and postmortem neuropathology [95], and then were further
categorized as either dying on or off ART. Fourteen of HIV-1-
positive patients in this study died with HAD; one patient
designated ART2 in Table 1 was classified as MND based on his
lack of emotive/behavioral criteria [96]. Patients who displayed
HAND without HIVE histopathology at autopsy met American
Academy of Neurology criteria for HAND regardless of ART
status. This definition requires demonstration of cognitive and
functional impairments, and the presence of emotive or motoric
phenomena [96]. Except for patient ART2, patients with HIVE
were similarly impaired, regardless of ART status, or had histories
of HAND on medical record review. Patients felt to have cognitive
impairments) due to non-HIV-1 causes (neuropsychological
impairment – other, as described in [95] were excluded. All
patients dying on ART had substantive treatment histories,
ranging 1 to 7 years prior to demise. The ART regimens at
death had a mean duration of 16 months (range, 3 months to 3
years). For five of seven patients on ART, treatment compliance
estimates were made by self-reported 4 day recall [97]. HIV-1-
negative subjects were chosen on the basis of normal neurological
function (as determined by chart review) and normal neurohistol-
ogy. All neurohistologic diagnoses were rendered by a board-
certified neuropathologist (SM) and a minimum of 50 sections
were examined for each brain. The following brain pathology
definitions were used in the present work (Table 1): Normal: no
brain pathology; HIVE: HIV encephalitis; HIVE*: HIVE was
limited to the basal ganglia (pid 30015); Minimal: minimal
histopathological changes including trivial microscopic abnormal-
ities such as an isolated vermal scar (pid 10119), a venous ectasia
(pid 10063), atherosclerosis and minimal perivascular inflamma-
tion sub-threshold for diagnosis (pid 10001), and minimal
perivascular inflammation sub-threshold for diagnosis (pid
10015). At the time of autopsy, coronal sections of brain were
snap-frozen and maintained in 285uC until sub-dissection. Effort
was made to keep the post mortem interval (PMI) to a minimum;
the PMI for subjects in this study are listed in Table 1. Brain
samples for this analysis were obtained from the centrum
semiovale (deep white matter) at the coronal level of the genu of
the corpus callosum. Multiple samples from the same region were
dissected for gene expression profiling, real-time PCR (QPCR),
and protein assays. Equivalent regions from the contralateral
hemisphere were formalin fixed and utilized for immunohisto-
chemistry.
DNA and RNA isolation from human brain and reverse
transcription
Total DNA and RNA were isolated from human brain tissue
by, respectively, DNeasy Blood and Tissue Kit and RNeasy Mini
Kit (Qiagen, Valencia, CA) according to the manufacturer’s
protocol. RNA was quantified by spectrophotometry and RNA
quality was verified by spectrophotometry and agarose gel
electrophoresis. RNA was then treated with DNAse I (Fisher
Healthcare, Houston, TX). cDNA was synthesized using the
Superscript First-Strand Kit (Invitrogen, Carlsbad, CA) for
quantitative analysis and the WT-Ovation
TM RNA Amplification
System (NuGEN Technologies, Inc., San Carlos, CA) for relative
analysis according to the manufacturer’s protocol.
Virus load in the brain
Viral RNA and DNA burdens in human brain were determined
by quantitative real-time PCR using primers designed based on
HIV-1 consensus sequences for the group of patients in this study.
We first screened patient brain samples for the presence of HIV-1
content by a standard nested PCR for viral DNA or RNA (cDNA)
as previously described [98]. To achieve broad detection of diverse
Clade B HIV-1 species, first-round PCR was performed using
custom designed primers for a conserved Clade B gag consensus
sequences: SQ5 (+)5 9-CAA ATG GTA CAT CAG GCC ATA
TCA CC-39 and SQ39 (2)5 9-CCC TGA CAT GCT GTC ATC
ATT TCT TC-39. For nested PCR step we used primers SQ59
(above) and SK39 [99]; the PCR products were resolved on an
agarose gel and detected by Southern Blot hybridization with
(
32P)-labeled probe SK19 [99] (Supplementary Figure S1). The
HIV-1 gag nested PCR amplicons from individual HIV-1 DNA
positive patients were sequenced and used to design patient
consensus primers (59 (+) QSQ5 59-ACC CAT GTT T(T/A)C
AGC ATT ATC AGA-39 and 39 (2) QSQ3 59-GAT GTC CCC
CCA CTG TGT TT-39) and Taqman probe (HSQP 6FAM-AGC
CAC CCC ACA AGA-MGBNFQ). For real-time PCR amplifi-
cation, 2 ml of brain tissue DNA or 5 ml of cDNA were combined
with 26 Universal Master Mix (Applied Biosystems, Carlsbad,
CA), 900 nM consensus primer (custom synthesized by Invitrogen)
and 200 nM probe (synthesized by Applied Biosystems; QPCR
conditions were essentially as described [100]. Standard curve for
viral DNA and cDNA quantification was constructed from graded
amounts of HIV-1 NL4-3 plasmid DNA. Viral DNA burdens were
normalized to total cellular DNA content by b-globin amplification
and expressed as HIV-1 DNA copies/number of cells calculated
from a b-globin DNA standard curve, with 2 copies of b-globin gene
equaling one cell. Viral RNA burdens were normalized by tissue
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) content and ex-
pressed as number of viral copies in 1 mg tissue RNA [100].
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Microarray experiments were conducted at the Bionomics
Research and Technology Center in EOSHI University of
Medicine and Dentistry of New Jersey. Total RNA were extracted
from tissue samples using the RNeasy Mini Kit (Qiagen) followed
by DNase I treatment. RNA qualities were assessed by
electrophoresis using the Agilent Bioanalyzer 2100 and spectro-
photometric analysis prior to cDNA synthesis. Fifty nanograms of
total RNA from each sample were used to generate a high fidelity
cDNA for array hybridization using NuGen WT-Ovation Pico
RNA Amplification. Detailed protocols for sample preparation
can be found at http://www.nugeninc.com. After fragmentation
and biotin labeling using NuGen Encore Biotin Module, the
samples were hybridized to Affymetrix Human Genome 133 plus
2.0 arrays. Washing and staining of all arrays were carried out in
the Affymetrix fluidics module as per the manufacturer’s protocol.
The detection and quantitation of target hybridization was
performed with an Affymetrix GeneChip Scanner. Data were
assessed for array performance prior to analysis. The majority of
patient samples were analyzed in duplicates starting from the
cDNA synthesis step; in some cases second analysis was on an
adjoining brain sample.
Microarray data analysis
The .cel data files generated by the Affymetrix microarray
hybridization platform were analyzed by the ArrayAssist software
(Stratagene, Santa Clara, CA). Probe level analysis was performed
using the RMA algorithm. After verification of data quality by
Affymetrix internal controls and signal distribution analysis as
described in Stratagene ArrayAssist Protocol, data was trans-
formed using variance stabilization and logarithm transformation
with a base of 2. Fluorescence values were normalized by mean
intensities of all chip samples. Means of normalized expression
values were calculated for duplicate samples from each individual,
and these values were either used directly in some analytical
programs (see below) or employed to calculate fold change (FC) in
the transcript compared to HIV-1-negative controls. Genes
showing FC values above 1.5 or below 21.5 and unpaired t-test
p-values of ,0.05 were defined as significantly changed. In some
analyses we applied a t-test cutoff of p,0.01. To test for effect of
antiretroviral treatment, we calculated the FC for significantly
modulated transcripts separately from untreated and treated
patients, the latter subdivided into all-treated and a subset without
two known low-compliant patients, versus uninfected controls. We
also compared directly normalized expression values of selected
transcripts from treated and untreated patients to generate the
treated versus untreated FC values that were not filtered through
HIV-1-negative controls.
To compare brain samples of all the individuals included in the
study we clustered the expression profiles using unsupervised
Hierarchical Clustering (Average Linkage Clustering) and heat-
map visualization software from Genesis [101] available at http://
genome.tugraz.at/. This type of analysis allows us to identify the
similarities and differences in the expression patterns of groups of
patients and/or transcripts. For broad characterization of gene
expression changes in untreated and treated patients we conducted
gene set and gene ontology analysis using GAzer [50] (http://
expressome.kobic.re.kr/GAzer/index.faces). GAzer is a web-
based tool that identifies, by a parametric statistical analysis of
complete primary normalized microarray data, over-represented
sets of genes (functionally related genes) rather than individual
genes. This type of analysis compensates for the fact that small
changes not seen at the gene level are often detected when the
gene set as a whole is examined [50,51]. When analysis was limited
to smaller sets of genes defined as differentially expressed, we
performed functional categorization of gene families by EASE
[102], available at the NIH web site (http://david.abcc.ncifcrf.
gov/). The predicted biological pathway and network relationships
among differentially expressed genes in our array datasets were
identified using the Search Tool for the Retrieval if Interacting
Genes/Proteins (STRING) (http://string-db.org/) [89].
Gene expression validation by QPCR
Changes in expression of selected genes identified by micro-
arrays analysis were validated in the same or adjoining brain
samples by QPCR using Taqman chemistry and probes from the
Universal Probe Library (Roche, Indianapolis, IN). Primers were
designed using the online ProbeFinder software available at the
Roche Universal Probe Library Assay Design Center (http://
www.roche-applied-science.com). The QPCR reactions contained
2 ml of cDNA generated from tissue RNA obtained as described
above, 10 mlo f2 6 Universal Master Mix (Applied Biosystems-
ABI), 0.2 ml of each forward and reverse primers at 200 nM,
0.2 ml of probe at 100 nM, and RNAse/DNAase-free water. All
reactions were performed in duplicate and were run in a 7500
real-time PCR system (ABI). Raw data was analyzed using the
7500 System SDS Software (ABI). Data was normalized using 2
housekeeping genes, GAPDH and ribosomal protein S18 (RPS18) to
assure reproducibility. Relative quantification employed the
comparative threshold cycle method (Applied Biosystems Techni-
cal Bulletin nu2).
Immunohistochemistry
For immunohistochemical analysis, formalin fixed blocks were
taken from the frontal white matter of the autopsy brains of 4
normal, 6 HIV-1-non-treated, and 4 HIV-1-ART-treated indi-
viduals. A microarray block consisting of 3 tissue punches diameter
of 1 mm) from each block was constructed. 5 mM serial sections
were cut and immunohistochemistry performed with an array of
antibodies listed in the Table 2.
Formalin-fixed, paraffin-embedded sections were deparaffinized
with xylenes, hydrated in graded alcohols, and incubated with 3%
H2O2 in methanol. Following washing, sections were boiled in
Target retrieval solution (DAKO Corp., Carpinteria, CA),
subsequently incubated in a serum free protein blocking solution
and then incubated with the primary antibodies indicated in
Table 2. CD45 (PTPRC) was incubated overnight at 4uC and the
all the remaining antibodies for 1 h at room temperature. Primary
antibodies were detected with peroxidase anti rabbit or mouse IgG
ImmPRESS (DAKO Corp.) reagent and counterstained with
hematoxylin. Slides were visualized in a light microscope and
either one, three or six 0.03 mm
2 areas of white matter staining
Table 2. Antibodies used for immunohistochemistry.
Antigen Dilution Antibody Type Source
C3c complement 1:3000 Rabbit polyclonal DakoCytomation
CD45, leukocyte
common antigen
1:100 Mouse monoclonal DakoCytomation
CD68/KP1 1:1000 Mouse monoclonal DakoCytomation
HLA-DP, DQ, DR 1:500 Mouse monoclonal DakoCytomation
MAP2 1:200 Mouse monoclonal Sigma
PCNA 1:1000 Mouse monoclonal DakoCytomation
doi:10.1371/journal.ppat.1002213.t002
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Nikon Coolpix II digital camera attached to the microscope by a
Coolpix MDC lens. The intensity of illumination and position of
sub-stage condenser on the microscope were constant for all
images. The number of areas taken depended on the type of
quantitative analysis that followed. The percentage area occupied
by cells immunoreactive for CD68, CD45 and HLA DP, DQ, DR
was quantitated by analysis of six 0.03 mm
2 images using a
proprietary automated morphometric analysis software [103]. The
mean intensity of MAP2 and STAT1 staining was analyzed on
one 0.03 mm
2 image, utilizing Image J software (http://rsbweb.
nih.gov/ij/). Each image was converted to 8-bit grayscale and a
mean gray value of the pixels in the full photographic image was
measured after a background subtraction and inversion were
performed. For C3c and PCNA, cell counts were done by eye
using either three 0.03 mm
2 (C3c) or the full punch (PCNA).
Statistical analysis was performed using StatView (V.5.0.1) (Adept
Scientific, Bethesda, MD). The principal statistical test used was
the Analysis of Variance for single comparisons (ANOVA).
Follow-up post-hoc tests were conducted when required. Signif-
icance values were set at 0.05 and below.
Correlation analysis
Correlation analysis between virus loads in plasma, CSF, or
brain and gene expression in the brain was performed using the
Pearson’s correlation formula in Microsoft Excel software (Micro-
soft Corporation, Redmond, WA). Transcripts showing positive
(.0.5) or negative correlation (,20.5) were categorized into
biological functional pathways using EASE software.
Microarray data repository
The microarray results presented here are available in the Gene
Expression Omnibus database (www.ncbi.nlm.nih.gov/geo) in a
MIAME compliant format under accession number GSE28160.
Gene accession numbers
The Gene ID numbers for the genes mentioned in the text are
listed below. The ID number corresponds to the ‘National Center
for Biotechnology Information database’ (http://www.ncbi.nlm.
nih.gov/gene): CD4 (920), C3 (718), CD68 (968), PTPRC (5788),
CDK5R2 (8941), MAP2 (4133), CPLX1 (10815), SYNPR
(132204), NFEL (4747), SYT4 (6860), CD74 (972), C1QC (714),
IFIT2 (3433), CR1 (1378), CXCL2 (2920), HLA-DQB1 (3119),
IFIT1 (3434), IFI44 (10561), MX1 (4599), OAS1 (4938), STAT1
(6772), PCNA (5111), MOBP (4336), MYT1 (4661), MBD (4155),
IFI30 (10437), CTSS (1520), IFITM1 (8519), B2M (567), CD14
(929), APOC-I (341), APOC-II (344), HBA-2 (3040), HBB (3043),
IFI16 (3428), TLR7 (51284), SYN1 (6853), SYN2 (6854),
GABRG2 (2566), CDC42 (998), CDK5R1 (8851), GAPDH
(2597), RPS18 (6222).
Supporting Information
Figure S1 HIV-1 brain burdens of study subjects. A.
Analysis of HIV-1 brain burdens in patient tissues by real-time
PCR. Control: uninfected patients; HAND: patients with HAND
without HIVE; HAND/HIVE: patients with HAND and HIVE;
ART: treated patients of either category. HIV-1 DNA copies were
prorated per 500,000 cells and HIV-1 RNA copies were per 1 mg
RNA. HIV-1 plasma burdens are shown for comparison. B.
Analysis of HIV-1 brain burdens by traditional PCR amplification
and Southern blot hybridization. b-globin was used for normali-
zation. For details, see Materials and Methods.
(TIF)
Figure S2 Hierarchical cluster analysis of study sub-
jects. The Figure represents enlarged image of the cluster panel
shown on the top of Figure 3A. The cluster tree shows computer-
generated phenotypic relationship between the subjects in the
study according to the presence and relative expression of 2073
HAND-associated transcripts listed in Supplementary Table S2.
Note close phenotypic relationship between 7 out of 8 untreated
HAND distinct from treated patients and controls. Treated
patients clustered mostly together in two inter-related clusters
with HIV-1-negative controls,
(TIF)
Table S1 Comparison of HAND and HAND/HIVE GO
pathways. The Table shows an extended list of significantly
altered GO pathways in untreated HAND and HAND/HIVE
datasets as defined by GAzer software. Significance of change in
GO pathways was determined by Z-score, p-and q-values, and
Bonferroni correction value; the data shown is delimited by Z-
scores.
(XLS)
Table S2 Gene changes in untreated HAND. The Table
shows a complete list of significantly changed transcripts and genes
in brain tissues from untreated HAND patients compared to HIV-
1 negative controls. FC: Fold-change, pv: t-test p-value.
(XLS)
Table S3 Gene changes in treated HAND. The Table
shows a complete list of significantly changed transcripts and genes
in brain tissues from treated HAND patients compared to HIV-1
negative controls. FC: Fold-change, pv: t-test p-value.
(XLS)
Table S4 HAND and ART GO pathways vs. controls. The
Table shows an extended list of significantly altered GO pathways
in untreated HAND vs. control (sheet 1), ART vs. control (sheet 2),
and ARTa vs. control (sheet 3); all as defined by Gazer software.
Significance of change in GO pathways was determined by Z-
score, p-and q-values, and Bonferroni correction value; the data
shown is delimited by Z-scores.
(XLS)
Table S5 List of genes validated by real-time PCR. The
Table shows average of 2 independent QPCR experiments for
each gene listed; microarray results are shown for comparison.
QPCR was conducted in duplicates on tissue samples adjoining to
those used for microarray analysis; Taqman chemistry was
employed as described in Materials and Methods.
(PPT)
Table S6 Direct comparison of ART and HAND gene
expression datasets. The Table shows significantly changed
transcripts and genes derived by direct comparison of RMA values
from complete ART and HAND microarray datasets, without
prior normalization to HIV-1 negative controls. Also shown are
expression values for the same genes in ART vs. HIV-1 negative
control. Separate tabs for up- and down-regulated genes.
(XLS)
Table S7 Comparison of ART and HAND gene expres-
sion datasets for GO pathways. Data was analyzed as in
Table S6 but using GAzer software to define gene ontology
pathways. Significance of change in GO pathways was determined
by Z-score, p-and q-values, and Bonferroni correction value; the
data shown is delimited by Z-scores.
(XLS)
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treated and untreated patients. A gene whose expression
was not significantly different in the HAND versus ART
comparison (p.0.05) was considered similarly dysregulated in
both groups of patients relative to uninfected subjects. FC: Fold-
change, pv: t-test p-value.
(XLS)
Table S9 Gene expression commonalities with other
array studies of brain tissues from patients with HAND.
(PPTX)
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